BELFAST, UNITED KINGDOM, (26th September 2023) Diaceutics, a leading technology and solutions provider to the pharmaceutical industry, today announces details of its planned CEO transition. Co-founder and current Chief Innovation Officer Ryan Keeling will assume the role of CEO designate, effective immediately. Ryan Keeling will work closely with the current CEO and Founder Peter Keeling during this transition period. Thereafter, Peter’s primary focus will be to accelerate the corporate development of Diaceutics as a board member.
This leadership transition has been carefully planned to strengthen Diaceutics' board and position the company for continued growth and success in the rapidly evolving precision medicine landscape; Diaceutics core market. Peter Keeling will remain a key advisor to Diaceutics, ensuring a seamless transition of leadership and continued performance in advancing precision medicine and delivering on its purpose to benefit patients worldwide.
Peter Keeling co-founded Diaceutics in 2005 and has led the growth of the Company from a niche consulting service provider to a high margin, high growth diagnostic commercialisation platform, leading the business to IPO in 2019.
Ryan joined Diaceutics in 2006 and became a member of the Board on IPO in 2019. The Company now serves 21 of the top 30 global pharma companies, with 161 people across Europe and North America and a network of 900 laboratories worldwide.
Ryan is widely recognised as the visionary behind the Diaceutics DXRX platform and follow on DxRx Signal products which are revolutionising the way pharmaceutical companies approach the commercialization of medicines. His deep industry knowledge and technical expertise make him the ideal choice to lead Diaceutics into its next phase of growth and innovation. During his tenure with Diaceutics, Ryan has underpinned the Company’s growth, holding the key roles of Chief Commercial Officer, Chief Operating Officer and most recently, Chief Innovation Officer where he has led the Group’s innovation
Peter Keeling's inspirational leadership has been pivotal in shaping Diaceutics into a true force in the field of precision medicine. His strategic acumen and unwavering commitment to the company's mission have not only ensured its continued success but have also positioned it for unprecedented growth and impact.
Peter Keeling expressed his confidence in Ryan's ability to lead the company, stating, "It has been an incredible journey building Diaceutics from the ground up. I am immensely proud of what we have achieved, and I am excited for the future. Ryan and I have worked closely together since the inception of Diaceutics, and I have every confidence in his ability to lead the company to even greater heights."
Ryan Keeling, CEO Designate of Diaceutics, commented, "I am deeply honoured to take on this new role. The team of people we have at Diaceutics are very special, they are a team with a strong purpose at their core and over the years we have built a culture that any new CEO would be delighted with. Couple the people with best in class tech, a data repository that is the envy of the Precision Medicine world and a 15-year track record with the world’s largest pharma companies, there is significant opportunity to do something really extraordinary here.
Peter and I have been on an incredible journey together, and I look forward to building on the strong foundation we have created. We extend our heartfelt gratitude to him for his relentless dedication, exceptional strategic guidance, and unwavering commitment to our purpose. Under Peter's leadership, Diaceutics has not only thrived but has also become a global beacon of innovation and excellence. His foresight and strategic acumen have positioned our company for unparalleled growth and impact.”
For media enquiries contact:
Diaceutics PLC Tel: +44 (0)28 9040 6500
Corporate Marketing & Communications Director [email protected]
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostic Network®.